Drug Profile
Interleukin-2 inhalation - Immunservice
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Immunservice
- Class Adjuvants; Antineoplastics; Immunotherapies; Interleukins; Lymphokines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer metastases
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for clinical-Phase-Unknown development in Cancer-metastases in Germany (Inhalation)
- 26 Feb 2016 Interleukin-2 inhalation - Immunservice receives Orphan Drug status for Cancer metastases in European Union